Traws Pharma, Inc.
TRAW
$1.88
$0.021.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 4,694.74% | 1.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4,694.74% | 1.79% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 4,694.74% | 1.79% | |||
| SG&A Expenses | -38.60% | -20.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.30% | -1.39% | |||
| Operating Income | 75.99% | 1.42% | |||
| Income Before Tax | -104.26% | 171.82% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -104.26% | 171.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -104.26% | 171.82% | |||
| EBIT | 75.99% | 1.42% | |||
| EBITDA | 76.01% | 1.40% | |||
| EPS Basic | -104.96% | -91.86% | |||
| Normalized Basic EPS | -105.09% | 131.75% | |||
| EPS Diluted | -105.26% | -92.14% | |||
| Normalized Diluted EPS | -105.28% | 130.65% | |||
| Average Basic Shares Outstanding | -16.44% | 126.21% | |||
| Average Diluted Shares Outstanding | -19.32% | 134.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||